Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
A pilot trial was initiated for chronic myeloid leukaemia patients, which employed imatinib for remission induction, followed by reduced-intensity conditioning and an in vivo T-cell depleted graft. Out of nine patients, six experienced a molecular relapse and one patient had a haematological relapse at a median interval of 5 months after transplantation. Five relapsing patients achieved a 2nd molecular remission after treatment with either donor lymphocyte infusions (n = 4) or imatinib (n = 1). Two of nine patients died due to infectious complications. The probability of survival 2 years after transplant was 74% (95% CI 42-100%).
Ringhoffer
Mark
M
Third Department of Medicine, University Hospital of Ulm, Ulm, Germany.
Harsdorf
Stephanie von
Sv
Schmitt
Michael
M
Wiesneth
Markus
M
Zenz
Thorsten
T
Stilgenbauer
Stephan
S
Greiner
Jochen
J
Döhner
Konstanze
K
Marx
Martin
M
Döhner
Hartmut
H
Bunjes
Donald
D
D000328:Adult; D001549:Benzamides; D005260:Female; D016044:Fusion Proteins, bcr-abl; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D008212:Lymphocyte Depletion / Q000379:methods*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012008:Recurrence; D012306:Risk; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl